National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 36 of 66
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
NCT00662506
Viral Therapy in Treating Patients With Metastatic Melanoma
NCT00651157
Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors
NCT00622414
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
NCT00665470
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
NCT00667394
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
NCT00324987
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
NCT00576654
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas
NCT00644072
Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
NCT00923845
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
NCT00637481
IMC-A12 in Treating Patients With Advanced Liver Cancer
NCT00639509
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
NCT00617708
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
NCT00577889
Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia
NCT00571558
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
NCT00923273
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
NCT00625846
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
NCT00923910
Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)
NCT01131312
Satraplatin and Prednisone to Treat Prostate Cancer
NCT00634647
Phase II Study of Vandetanib in Individuals With Kidney Cancer
NCT00566995
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
NCT01445405
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
NCT00588991
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer
NCT00450749
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
NCT00659360
Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
NCT00516295
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
NCT00602459
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
NCT00607594
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
NCT00397982
IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor
NCT00609141
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
NCT00602771
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
NCT00540722
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
NCT00612612
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
NCT00610311
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
NCT00612222
Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
NCT00551070
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00357760
Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
NCT00559949
Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
NCT00972205
Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage
NCT00589290
Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
NCT00588809
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
NCT00538187
Vandetanib to Treat Advanced Kidney Cancer
NCT01372813
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT00553644
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
NCT01445392
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
NCT00553332
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer
NCT00589472
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
NCT00604721
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
NCT00528645
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00462826
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
NCT00563290
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.